Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), 36 biosimilars have been approved, 22 of which have launched. Notably, since our last update, Genentech filed another suit relating to Herceptin, and Regeneron filed an antitrust suit against Amgen relating to Praluent.